The massive dilution from this offering, combined with the company's pre-revenue status and $17M market cap, signals acute capital needs. Monitor for further cash burn and potential need for additional financing within the next 12 months. The 45-day lock-up provides a temporary floor, but the overhang from the common warrants (exercisable in 6 months) will likely cap any upside.
Price Chart
Executive Summary
Pluri Inc. raised approximately $2.98 million in net proceeds through a registered direct offering and concurrent private placement, selling 1,200,000 common shares at $1.50 each, pre-funded warrants for 1,028,940 shares at $1.49999 each, and issuing common warrants to purchase up to 2,228,940 shares at $1.65. The offering is highly dilutive, adding over 2.2 million shares of potential dilution on top of the 2.2 million shares sold, representing a massive increase to the company's $17M market cap base. Proceeds are earmarked for corporate development and working capital, signaling ongoing cash needs for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Pluri raised ~$2.98M net from a registered direct offering and concurrent private placement.
- Sold 1,200,000 common shares at $1.50/share and pre-funded warrants for 1,028,940 shares at $1.49999/share.
- Issued common warrants to purchase up to 2,228,940 additional shares at $1.65, exercisable starting 6 months after closing for 5 years.
- Total potential dilution from shares + pre-funded warrants + common warrants is ~4.46 million shares against a ~$17M market cap.
- Net proceeds of ~$2.98M will be used for corporate development, general purposes, and working capital.
- Placement agent A.G.P./Alliance Global Partners received a 6.50% cash fee plus up to $50,000 in expense reimbursement.
- 45-day lock-up on the company and insiders from issuing or selling additional shares.
- The offering was conducted under an existing S-3 shelf registration statement (File No. 333-273347).
Financial Impact
~$2.98M net proceeds raised; total potential dilution of ~4.46M shares (shares + pre-funded warrants + common warrants) against a ~$17M market cap, representing a ~26% immediate dilution and up to ~100% potential dilution if all warrants are exercised.
Risk Factors
- Extreme dilution from the offering and potential warrant exercise could further depress the stock price.
- Pre-revenue biotech with no disclosed revenue or pipeline catalysts; cash burn rate unknown but likely high relative to the ~$2.98M raised.
- The 45-day lock-up period may create a sharp sell-off once it expires.
- Common warrants at $1.65 are out-of-the-money at the $1.50 offering price, but any price appreciation could trigger massive additional dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-094638 |
| Document: 0001213900-26-094638-index.html | 0001213900-26-094638 |
| Document: 0001213900-26-094638.txt | 0001213900-26-094638 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.05 | awaiting T+20 | — | $1.12 (−6.67%) |
Oct 16, 2026 11d ago | EFFECT | $0.9299 | awaiting T+20 | — | $1.12 (−20.44%) |
Oct 6, 2026 20d ago | S-1 | $1.04 | awaiting T+20 | — | $1.12 (+7.69%) |
Aug 28, 2026 8w ago | 424B5 | $1.53 $0.9700 | ▲ +36.60% | ▲ +36.86% | $1.12 (+26.80%) |
Aug 28, 2026 8w ago | 8-K | $1.53 $0.9700 | ▲ +36.60% | ▲ +36.86% | $1.12 (+26.80%) |
Aug 17, 2026 10w ago | 8-K | $1.63 $1.19 | ▼ −26.99% | ▼ −26.00% | $1.12 (−31.29%) |
Aug 17, 2026 10w ago | Press Release | $1.60 $1.17 | ▼ −26.61% | ▼ −24.63% | $1.12 (−30.00%) |
Jul 14, 2026 14w ago | 8-K | $1.75 $1.63 | ▲ +7.14% | ▲ +9.49% | $1.12 (+36.00%) |
Jun 22, 2026 18w ago | 8-K | $2.10 $1.82 | ▼ −13.13% | ▼ −14.29% | $1.12 (−46.54%) |
Apr 23, 2026 26w ago | DEFA14A | $3.35 $2.30 | ▼ −31.34% | ▼ −35.37% | $1.12 (−66.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers